Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.

Shukui Qin,Zhendong Chen,Weijia Fang,Zhenggang Ren,Ruocai Xu,Baek-Yeol Ryoo,Zhiqiang Meng,Yuxian Bai,Xiaoming Chen,Xiufeng Liu,Juxiang Xiao,Gwo Fuang Ho,Yimin Mao, Xin Wang,Jieer Ying,Jianfeng Li,Wenyan Zhong,Yu Zhou,Abby B Siegel,Chunyi Hao

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）

Cited 25|Views50
No score
Abstract
In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined